Placeholder Banner

The 2016 BIO World Congress on Industrial Biotechnology Closed with a Record Number of Partnering Meetings

April 25, 2016

San Diego, California (April 20, 2016) - The 2016 BIO World Congress on Industrial Biotechnology, the largest international industrial biotech event, concluded today at the San Diego Convention Center in San Diego, CA. This year’s Conference drew around 907 industry leaders from 529 companies, 32 countries and 31 states, as well as the District of Columbia. Organized by the Biotechnology Innovation Organization (BIO), the World Congress on Industrial Biotechnology hosted more than 1,961 partnering meetings, nearly a 40% increase from the 2015 BIO World Congress.

“From our robust plenary sessions, to the record number of partnering meetings, the 2016 World Congress was a resounding success. This event continues to provide leaders with the opportunity to showcase the best of the industrial biotech industry and form connections and partnerships that will drive growth in the sector for years to come,” said Brent Erickson, Executive Vice President, Industrial & Environmental Section at BIO. “For the first time, this year’s BIO World Congress on Industrial Biotechnology brought together presenters right out of the tech transfer phase of development, so attendees had a front row seat to the latest industry innovations. It looked very much like the start of a new cycle of commercialization right here at the World Congress.”

The World Congress featured a dynamic group of plenary speakers from Astronaut Catherine “Cady” Coleman, PhD, National Aeronautics and Space Administration (NASA) to Michael “Miki” Knutzen, Global Program Director, PlantBottle, The Coca-Cola Company to Jonathan S. Wolfson, Chief Executive Officer of TerraVia.

Educational programming included 280 speakers and 48 sessions in 8 educational tracks which addressed the latest in Advanced Biofuels and Biorefinery Platforms; Algae, Biomass Supply and Specialty Crops; Growing Global Biobased Markets; Renewable Chemical and Biobased Materials; Research Presentations; Specialty Chemicals, Food & Nutritional Ingredients; Synthetic Biology and Genomics Research; and Technical Presentations. For session highlights and editorial, visit www.biotech-now.org.

The BIO Exhibition featured more than 40 exhibitors and sold over 5,000 square feet.

To help kick off the Conference, BIO hosted a pre-conference Workshop titled “Growing a Billion Ton Bioeconomy in the United States,” which spurred discussion on the potential to grow the national bioeconomy. BIO also held a workshop titled “What Investors Require When Making a Bioeconomy Investment” that focused on a series of crucial decisions potential investors consider when determining whether or not to invest in a company or technology. BIO’s final Workshop looked at how to “Build a Young Scientist Pipeline for a More Diverse Science Future.”

BIO also held an Intellectual Property Symposium as part of the 13th Annual World Congress on Industrial Biotechnology. The IP Symposium: “Where IP meets IB” took place on April 20, 2016 and consisted of two panels of experts who highlighted the value of intellectual property in industrial biotechnology.

BIO named J.Craig Venter, Ph.D as the recipient of its 2016 George Washington Carver Award for innovation in industrial biotechnology. Dr. Venter is founder and president of the J. Craig Venter Institute as well as Synthetic Genomics Inc., a privately held company developing and commercializing genomic-driven solutions to address global energy and environmental challenges. After receiving the award at the World Congress, Venter provided heartwarming remarks to attendees.

BIO also awarded Anna Rath, Chief Executive Officer of NexSteppe, with the prestigious BIO Rosalind Franklin Award for Leadership in Industrial Biotechnology. This award was established to put the spotlight on a pioneering woman in the industrial biotechnology sector who has made significant contributions to the advancement of the biobased economy and biotech innovation. Her remarks will be available here later this week.

Lastly, BIO presented Dr. Ganesh Kishore, CEO of MLSCFI and co-Managing Partner of Spruce Capital Partners, the first annual BIO Leadership and Legacy Award during the Conference. The new award was created to honor an individual who has shown exemplary leadership and who has dedicated a significant portion of their career to advancing industrial biotechnology and growing the biobased economy.

For BIO 2016 videophotos, and more, visit convention.bio.org.

The 2017 BIO World Congress on Industrial Biotechnology will take place July 23-26 in Montréal, Canada at the Palais des congrès de Montréal (Montreal Convention Center). 

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…